Hawaii may soon be more than just Paradise. It may also be a psychedelic therapy hub. A new state measure aims to legalize psilocybin, the hallucinogenic compound in certain mushrooms. The new bill was introduced by democratic Senators Stanley Chang, Laura Clint Acasio, Les Ihara Jr., and Maile Shimabukuro. If approved, Hawaii’s Department of Health would establish “designated treatment centers for the therapeutic administration of psilocybin and psilocyn.” The legislation would also remove the substances from the state’s list of Schedule 1 controlled substances. The proposed measure comes less than a year after the Aloha State saw legislation introduced to approve the study of psychedelic mushrooms. There are currently dozens of studies underway across the globe looking at psilocybin as a viable treatment option for a range of mental health issues. In particular, psilocybin is showing potential in treating patients diagnosed with treatment-resistant depression. If passed, the measure would also see the creation of a seven-person review panel aimed at assessing the policy change. The move comes on the heels of similar announcements by California and Florida legislators. Last November, voters in the nation’s capital and in Oregon decriminalized psychedelics. Oregon also became the first state to legalize psilocybin therapy. It now will develop standards for certifying therapists and treatment. Read more at: https://psychedelicspotlight.com/hawa… **Get the latest industry news around all things psychedelics by visiting our website and be sure to subscribe to our newsletter to never miss a thing.
Similar Posts
Interview With Rabbi Zac Kamenetz
Founder and CEO of Shefa, and Co-Founder of the Jewish Psychedelic Summit, Rabbi Zac Kamenetz, speaks about the upcoming summit and the connection between Judaism and psychedelics.
Interview With Jemie Sae Koo
In this episode of the Psychedelic Spotlight podcast, we feature Jemie Sae Koo, CEO and Founder of Psychable.
Important UPDATE : MindMed’s 2020 Year-End Financial Results [ Good News for MMED / MMEDF! ]
Hey Psychedelic Investors! For those of you following MindMed, today’s episode is based on MindMed’s press release where MMED announced their 2020 year-end Financial results.
What was covered in MindMed’s press release?
1. MMED ‘ s total assets
2. MindMed’s Net Cash Operating Activities
3.MMEDF ‘s Net loss
4. The company’s Cash on Hand
5. The date and hour for MindMed ‘s earnings call
MMED / MMEDF / MMQ ‘ stock has been experiencing a little fall lately… As long as the price doesn’t fall below $2 USD, we should still be good-ish in terms of the NASDAQ stock price requirements.. Hopefully it won’t fall below that threshold!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/news/press-release/mindmed-announces-2020-year-end-financial-results-current-cash-balance-of-161-million-usd-203-million-cad-to-support-drug-development-pipeline-and-creation-of-psychedelic-medicine-tech-platform/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
Psychedelic Spotlight Interview with Timothy Ko
In this episode of the Psychedelic Spotlight podcast, we spend…
MindMed vs. atai Life Sciences (Everything You Need to Know Before Buying MNMD / MMED/ ATAI)
THE MINDMED VS. ATAI discussion you need to hear!
Prior to atai’s IPO on the NASDAQ stock exchange, we repeatedly said that when atai Life Sciences goes public, the company will become MindMed ‘s ( MNMD: NASDAQ) (MMED: NEO) top competitor.
Well, atai did IPO on June 18 under ticker symbol “atai”. For this reason, I invited Jason Najum from Microdose.buzz to have a conversation. In this episode, we have a general discussion about:
– MindMed’s flagship programs and the different businesses and programs ran under atai’s umbrella.
– The companies’ financial capability to run clinical trials.
-MindMed’s and atai’s potential to disrupt the way we treat mental illness within the next 5 to 10 years.
– Potential return on investment for retail investors.
Time Stamps:
0:00 – Intro
4:11 – What is atai’s mission?
6:24 – What is MindMed’s Mission
8:29 – atai’s clinical trial pipeline
19:45 – MindMed’s clinical trial pipeline
24:25 – How do MindMed and atai differ in business structure?
30:40 – Comparing the financials
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Enjoy the episode!
Check out Jason’s writing at:
https://microdose.buzz/
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Website: https://thepsychedelicinvestor.com/
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MNMD #Atai
Interview With Stephen Murphy
Stephen Murphy, Co-Founder of Prohibition Partners, chats about the upcoming PSYCH Investor Summit taking place on April 21, 2021.